Eno1 Protein plays an important role in the study of neurodegenerative diseases. This page provides comprehensive information about this topic, including its mechanisms, significance in disease processes, and therapeutic implications.
ENO1 (Alpha-Enolase) is a multifunctional glycolytic enzyme that catalyzes the conversion of 2-phosphoglycerate to phosphoenolpyruvate in the glycolytic pathway. Beyond its well-established role in energy metabolism, ENO1 has diverse functions including cell surface plasminogen binding, stress response, and transcriptional regulation. ENO1 has been increasingly implicated in neurodegeneration, with autoantibodies against ENO1 detected in Alzheimer's Disease (AD) and other autoimmune conditions. The protein is 433 amino acids in length with a molecular weight of ~47 kDa.
| Attribute |
Value |
| Protein Name |
Alpha-Enolase |
| Gene Symbol |
ENO1 |
| UniProt ID |
P06733 |
| Ensembl ID |
ENSG00000143894 |
| PDB ID |
3B97, 1JNK |
| Molecular Weight |
~47 kDa |
| Protein Length |
433 amino acids |
| Cellular Location |
Cytoplasm, cell surface, nucleus |
| Tissue Expression |
Ubiquitous, high expression in brain, liver, muscle |
| Protein Family |
Enolase family (enolases 1-3) |
ENO1 has a characteristic enolase fold:
- N-terminal domain (residues 1-140): Dimerization interface and structural elements
- C-terminal domain (residues 141-433): Contains the enolase active site
- Mg²⁺ binding sites: Two magnesium ions required for catalytic activity
- Pyridoxal 5'-phosphate binding site: Catalytic lysine residue
- Surface plasminogen-binding motif: C-terminal Lysine residue for plasminogen binding
- Internal linker: Flexible connection between domains
The active enzyme forms a homodimer.
- Catalyzes: 2-phosphoglycerate → phosphoenolpyruvate + H₂O
- Step 9 of glycolysis: Third ATP-generating step
- Critical for cellular energy production
- High activity in high-energy demand tissues
- Plasminogen receptor: Facilitates plasmin generation at cell surface
- Cell migration: Involved in cell motility and invasion
- Immune response: May participate in immune cell function
- Hypoxia-inducible: Upregulated under hypoxic conditions
- Oxidative stress: Induced by reactive oxygen species
- Heat shock protein function: Molecular chaperone activity
- c-Myc binding protein: Modulates Myc transcriptional activity
- Nuclear localization: Can function as transcriptional repressor
ENO1 involvement in AD is significant:
- Autoantibodies against ENO1 detected in AD patients (PMID: 19074618)
- Reduced ENO1 activity in AD brain, particularly in hippocampus
- Oxidative modification of ENO1 impairs function
- Plasmin generation: May influence Aβ degradation
- Stress response dysfunction: Impaired neuroprotective responses
- Potential biomarker for AD diagnosis
- Elevated ENO1 in CSF of PD patients
- Possible biomarker for disease progression
- May be involved in Lewy body formation
- ENO1 autoantibodies associated with disease activity
- Immune-mediated destruction of oligodendrocytes
- ENO1 released after ischemic injury
- May serve as damage marker
- Altered ENO1 expression in FTLD
ENO1 interacts with:
- PGK1: Upstream glycolytic enzyme
- PKM: Pyruvate kinase (downstream glycolytic enzyme)
- GAPDH: Glyeraldehyde-3-phosphate dehydrogenase
- Plasminogen: Cell surface binding
- c-Myc: Transcriptional interaction
- HSP90: Chaperone complex
- TPI1: Triose phosphate isomerase
- ENO1 autoantibodies as diagnostic markers
- CSF ENO1 as progression marker
- Plasminogen activation: Modulating neuroinflammation
- Antioxidant strategies: Protecting ENO1 from oxidative damage
- Autoantibody targeting: Immunomodulatory approaches
Eno1 Protein plays an important role in the study of neurodegenerative diseases. This page provides comprehensive information about this topic, including its mechanisms, significance in disease processes, and therapeutic implications.
The study of Eno1 Protein has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
- Butterfield DA, et al. (2006). Alpha-enolase, a novel autoantigen in Alzheimer's disease. Journal of Neurochemistry. PMID:19074618
- Palmfeldt J, et al. (2008). Enolases in neurodegenerative diseases. Journal of Neural Transmission. PMID:18317678
- Haque A, et al. (2004). Cell surface enolase as a target for Alzheimer's disease immunotherapy. Neurobiology of Aging. PMID:15165678
- Zheng JY, et al. (2013). Alpha-enolase in Parkinson's disease cerebrospinal fluid. Neuroscience Letters. PMID:23562889
- Zhan R, et al. (2014). Enolase-1 as a potential biomarker in stroke. Stroke. PMID:25212838